Literature DB >> 17475983

Twenty years of recombinant human growth hormone in children: relevance to pediatric care providers.

Dana S Hardin1, Stephen F Kemp, David B Allen.   

Abstract

Recombinant human growth hormone has revolutionized the management of children and adolescents with growth hormone deficiency and other growth disorders, but clinical and ethical controversies remain regarding diagnostic approach, optimal recombinant human growth hormone dose and duration, and expected outcomes. Management of pubertal and transitioning patients with growth hormone deficiency has also commanded increased attention. Recent clinical studies that demonstrate the positive health benefits of recombinant human growth hormone in children with cystic fibrosis, inflammatory bowel disease, and juvenile rheumatoid arthritis have not yet clarified issues about patient selection and appropriate long-term use. An understanding of current recombinant human growth hormone indications and controversies can facilitate patient evaluation and expedite referral for potential treatment. This review summarizes current indications for recombinant human growth hormone use, discusses clinical challenges, and provides recommendations for pediatricians caring for children who may be appropriate candidates for recombinant human growth hormone therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475983     DOI: 10.1177/0009922806293924

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  6 in total

1.  Dissolving microneedle patch for transdermal delivery of human growth hormone.

Authors:  Jeong Woo Lee; Seong-O Choi; Eric I Felner; Mark R Prausnitz
Journal:  Small       Date:  2011-01-04       Impact factor: 13.281

2.  COMPLIA: A 12-MONTH PROSPECTIVE, MULTICENTRE, NON-INTERVENTIONAL STUDY TO EVALUATE TREATMENT ADHERENCE AND TREATMENT SATISFACTION IN A GROWTH HORMONE DEFICIENT PAEDIATRIC POPULATION TREATED WITH NUTROPINAQ® A SOMATROPIN ANALOGUE.

Authors:  C P Dumitrescu; C Procopiuc; N Dumitriu; I Micle; M Anton; A Moisuc
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

3.  Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy.

Authors:  David R Weber; Stasia Hadjiyannakis; Hugh J McMillan; Garey Noritz; Leanne M Ward
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

4.  Final Height in Children with Idiopathic Growth Hormone Deficiency treated with Growth Hormone: Albanian experience.

Authors:  A Gjikopulli; L Grimci; L Kollçaku; S Tomori; P Cullufi; P Hoxha; Z Ylli
Journal:  Curr Health Sci J       Date:  2015-03-15

Review 5.  Endocrine therapy for growth retardation in paediatric inflammatory bowel disease.

Authors:  Mabrouka A Altowati; Richard K Russell; S Faisal Ahmed
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

6.  Medicalising short children with growth hormone? Ethical considerations of the underlying sociocultural aspects.

Authors:  Maria Cristina Murano
Journal:  Med Health Care Philos       Date:  2018-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.